Podcasts
Human Resources

Pharmacy Is a Quarter of Benefit Spend: A Framework for GLP-1 Coverage Decisions

Fizza Fatima NaqviSeptember 3, 20267 min read
Pharmacy Is a Quarter of Benefit Spend: A Framework for GLP-1 Coverage Decisions

Key takeaways

  • Rising pharmacy costs: Pharmacy benefits represent 25% of total healthcare spending (medcitynews.com).
  • GLP-1 utilization: 68% of employers report an increase in the use of GLP-1 medications for weight management (medcitynews.com).
  • Budgetary impact: Rising GLP-1 use is estimated to account for a full percentage point of overall cost growth for 2027 (fiercehealthcare.com).
  • Employer response: 59% of employers plan to implement cost-cutting changes to health benefits next year (fiercehealthcare.com).

Pharmacy benefits represent 25% of total healthcare spending (medcitynews.com). As these costs occupy a quarter of the total healthcare budget, the mechanisms driving pharmacy spend have become a central focus for benefits strategy. Recent data suggests that the projected increase in employer health benefits costs is the highest since 2003, marking the fifth consecutive year of rising costs (fiercehealthcare.com).

The mechanics of the 2027 cost spike

Marsh analysts have identified several drivers behind the projected increase in employer health benefits costs (fiercehealthcare.com). While many discussions focus on a single medication class, the actual cost trajectory is the result of multiple overlapping factors. These include provider consolidations, government funding that lags behind inflation, the introduction of advanced treatments, and the implementation of AI software for claims processing (fiercehealthcare.com). Additionally, the No Surprises Act’s Independent Dispute Resolution (IDR) process has emerged as an unintended driver of costs (fiercehealthcare.com).

Within this complex landscape, GLP-1 medications are a prominent factor. Marsh actuaries estimate that rising GLP-1 utilization accounts for a full percentage point of the overall cost growth projected for 2027 (fiercehealthcare.com). While a single percentage point may seem small in isolation, it represents a significant portion of the total growth trajectory when viewed against the backdrop of other rising costs (fiercehealthcare.com).

The human mechanism behind these numbers is often a shift in how employees access care. As new, highly effective medications enter the market, utilization patterns change. When a large segment of a population accesses a high-cost specialty drug, the financial impact is felt quickly in the pharmacy spend. This is not just about the price of the drug itself, but the cumulative effect of widespread adoption across a large workforce.

Few organizations can absorb health cost increases that outpace inflation without making difficult financial decisions (fiercehealthcare.com).

Why It Matters

Analyzing the GLP-1 coverage divide

The response to rising GLP-1 costs is not uniform across the employer community. There is a visible split in how organizations are approaching coverage for weight management. On one side, a significant majority of employers are seeing more employees ask for these medications (medcitynews.com). On the other side, some organizations are moving toward more restrictive policies. Specifically, 14% of employers have dropped or will drop GLP-1 coverage for weight management in 2027 (medcitynews.com).

One reading of this trend is that employers are moving toward a "value-based" model. Brenna Shebel noted that employers are becoming more selective in GLP-1 coverage for weight management, with a specific focus on utilization and value (medcitynews.com). This suggests a shift away from broad, inclusive coverage toward more controlled, clinical-driven access. This approach aims to ensure that high-cost medications are directed toward the employees who will derive the most clinical benefit, rather than providing blanket access.

The counter-reading to this selective approach is the potential impact on employee perception and wellness culture. If an employer provides coverage for some chronic conditions but denies it for weight management, it can create a perceived inequity in the benefits package. Employees often view health benefits as a core part of their total compensation. When coverage for a widely discussed medication is removed, it may impact the perceived value of the benefits program, even if the decision was made to ensure the long-term sustainability of the plan.

Comparing employer strategies for 2027

As we look toward the 2027 plan year, employers are facing a difficult mathematical reality. Without intervention, employers estimate that the cost of current plans would increase by 11% in 2027 (fiercehealthcare.com). This creates a tension between maintaining high-quality care and maintaining fiscal responsibility. The following table compares the different ways these trends are manifesting in the market.

Metric/Trend Data Point/Observation Source
Total Pharmacy Spend Share 25% of total healthcare spend (medcitynews.com)
GLP-1 Utilization Increase 68% of employers observing increases (medcitynews.com)
Projected 2027 Cost Increase 11% (if no actions are taken) (fiercehealthcare.com)
Employers Dropping GLP-1 Coverage 14% of employers (medcitynews.com)
Employers Planning Cost-Cutting 59% of employers (fiercehealthcare.com)

Analysis of these figures shows a clear trend toward "defensive" benefit design. With 59% of employers planning to make cost-cutting changes to health benefits next year, the focus is shifting toward plan design changes (fiercehealthcare.com). This might include higher deductibles, more stringent prior authorization requirements, or more limited formularies for specialty drugs.

What the data does not say

While the data provides a clear picture of cost trends and utilization, it has limitations. The data from the Marsh 2026 National Survey of Employer-Sponsored Health Plans is based on insights from more than 1,800 employers as of August 10, 2026 (fiercehealthcare.com). Because this is a survey of employers, it reflects the perspectives and observations of those organizations, rather than a direct clinical audit of every employee's medical record (fiercehealthcare.com).

Crucially, the data shows correlation, not necessarily direct causation in every instance. For example, while we know that rising GLP-1 use is a driver of cost growth, the data does not tell us whether the cost of the drugs is rising because of higher prices per unit, or simply because more people are using them (fiercehealthcare.com). It also does not account for the long-term "offset" effect. A central question in health economics is whether the high upfront cost of GLP-1 medications is eventually offset by lower costs in other areas, such as reduced cardiovascular events or diabetes complications. The current data does not provide a definitive answer on whether these long-term savings will materialize in time to offset the immediate pharmacy spend spike.

There is a shift toward greater transparency and accountability in the pharmacy benefit space (medcitynews.com).

Watch For

The tension between transparency and cost control

Brenna Shebel noted a shift toward greater transparency and accountability in the pharmacy benefit space (medcitynews.com). This is a critical mechanism for HR leaders to understand. In the past, pharmacy benefit managers (PBMs) often operated with less visibility into the specific rebates and discounts negotiated behind the scenes. As transparency increases, employers are gaining a clearer view of where their pharmacy dollars are actually going.

This transparency is a double-edged sword. On one hand, it allows HR leaders to make more informed decisions about plan design and vendor selection. On the other hand, it requires a much higher level of sophistication in how HR teams analyze their benefits spend. We can no longer rely on high-level summaries; we must look at the granular data of utilization, site of service, and specialty drug spend to understand the true drivers of our 2027 budget.

Analysis of this shift suggests that the role of the HR professional is moving from "administrator" to "analyst." As pharmacy spend becomes a larger portion of the budget, the ability to interpret complex pharmacy data becomes as important as the ability to manage employee relations or recruitment.

What HR can do on Monday morning

Given the projected 11% cost increase for 2027 (fiercehealthcare.com), HR teams should not wait until the next open enrollment period to begin addressing these trends. The following checklist provides practical, measurable steps to prepare for the upcoming plan year.

  1. Audit GLP-1 utilization rates: Request a report from your pharmacy benefit manager that specifically breaks down the current utilization rate of GLP-1 medications for weight management versus other clinical indications.
  2. Review the "Value" definition: If your organization is considering more selective coverage, define the specific clinical criteria that will trigger coverage. This should be based on medical necessity and clinical outcomes rather than just cost.
  3. Analyze the "Offset" potential: Ask your benefits consultants to model a three-year scenario: one where you cover GLP-1s broadly, and one where you implement restrictive coverage. Ask them to estimate the impact on other high-cost claims, such as cardiovascular or metabolic-related complications.
  4. Review plan design for 2027: Since 59% of employers are planning cost-cutting changes (fiercehealthcare.com), review your current plan design to see if your current deductible and out-of-pocket maximums are sufficient to absorb a 11% increase in total health costs (fiercehealthcare.com).

The goal is not to simply cut costs, but to manage them with intention. As we move into the 2027 plan year, the most successful organizations will be those that treat pharmacy spend not as an unpredictable variable, but as a managed clinical and financial strategy.

Written byFizza Fatima Naqvi

Fizza helps organizations strengthen the people side of performance, from recruitment and onboarding to performance management, training, and employee relations. An HR professional with an MBA in Human Resource Management and a BBA with Honours, she has hands-on experience as an HR Generalist, supporting recruitment, onboarding, performance appraisal, HR policy implementation, and employee training workshops. Her grounding in research methodology and statistical analysis informs how she approaches human resource questions.